Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation

Abstract Aims/Introduction Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are important incretin hormones. They are released from the gut after meal ingestion and potentiate glucose‐stimulated insulin secretion. Their release after meal ingestion and oral gluc...

Full description

Bibliographic Details
Main Authors:	Wathik Alsalim, Ola Lindgren, Bo Ahrén
Format:	Article
Language:	English
Published:	Wiley 2023-03-01
Series:	Journal of Diabetes Investigation
Subjects:	Glucagon‐like peptide‐1 Glucose‐dependent insulinotropic polypeptide Meal
Online Access:	https://doi.org/10.1111/jdi.13962

Similar Items

Roles of glucose‐dependent insulinotropic polypeptide in diet‐induced obesity
by: Yusuke Seino, et al.
Published: (2022-07-01)

Glucose‐dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in mice
by: Bo Ahrén
Published: (2022-10-01)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
by: Tsuyoshi Yanagimachi, et al.
Published: (2020-04-01)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
by: Enrique Z. Fisman, et al.
Published: (2021-11-01)

The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
by: Soyeon Yoo, et al.
Published: (2021-06-01)

Effects of passage through the digestive tract on incretin secretion: Before and after birth
by: Seiichi Tomotaki, et al.
Published: (2021-06-01)

Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature
by: Lampros G. Chrysavgis, et al.
Published: (2024-03-01)

Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
by: Ondrej Krystynik, et al.
Published: (2023-01-01)

Impacts of Glucose-Dependent Insulinotropic Polypeptide on Orthodontic Tooth Movement-Induced Bone Remodeling
by: Taisuke Yamauchi, et al.
Published: (2022-08-01)

Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function: Review on Mathematical Modelling Approaches
by: Giovanni Pacini, et al.
Published: (2022-05-01)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
by: Martin Haljeta Friedrichsen, et al.
Published: (2023-12-01)

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus
by: Sung Hoon Yu, et al.
Published: (2011-02-01)

Ingestion of coffee polyphenols increases postprandial release of the active glucagon-like peptide-1 (GLP-1(7–36)) amide in C57BL/6J mice
by: Yoshie Fujii, et al.
Published: (2015-01-01)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
by: Agnieszka Jakubowska, et al.
Published: (2024-02-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

Is the Secret in the Gut? SuperJump Activity Improves Bone Remodeling and Glucose Homeostasis by GLP-1 and GIP Peptides in Eumenorrheic Women
by: Sonya Vasto, et al.
Published: (2022-02-01)

Acute Dose–Response Effectiveness of Combined Catechins and Chlorogenic Acids on Postprandial Glycemic Responses in Healthy Men: Results from Two Randomized Studies
by: Aya Yanagimoto, et al.
Published: (2023-02-01)

Glucose-Dependent Insulinotropic Polypeptide Plasma Level Influences the Effect of n-3 PUFA Supplementation
by: Joanna Goralska, et al.
Published: (2022-08-01)

Serum and expression profiles of glucose-dependent insulinotropic polypeptide in correlation with cardiometabolic risk factors among patients with systemic lupus erythematosus
by: Nearmeen M Rashad, et al.
Published: (2019-01-01)

Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor
by: Fenghui Zhao, et al.
Published: (2021-07-01)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
by: Rizvi AA, et al.
Published: (2022-04-01)

Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
by: Alessia Costa, et al.
Published: (2022-01-01)

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses
by: Line Engelbrechtsen, et al.
Published: (2018-03-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Potential for Gut Peptide-Based Therapy in Postprandial Hypotension
by: Malcolm J. Borg, et al.
Published: (2021-08-01)

Glycemic and Metabolic Effects of Two Long Bouts of Moderate-Intensity Exercise in Men with Normal Glucose Tolerance or Type 2 Diabetes
by: Saeed Reza Eshghi, et al.
Published: (2017-07-01)

The Methylation Analysis of the <i>Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR)</i> Locus in GH-Secreting Pituitary Adenomas
by: Mattia Dalle Nogare, et al.
Published: (2023-05-01)

Tirzepatide – a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023-10-01)

Insulin and incretin responses to grazing in insulin‐dysregulated and healthy ponies
by: Danielle M. Fitzgerald, et al.
Published: (2019-01-01)

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
by: Shu-Chen Lu, et al.
Published: (2021-05-01)

Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis
by: Shangyu Chai, et al.
Published: (2023-08-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01)

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
by: Bartłomiej Stachyra, et al.
Published: (2023-04-01)

Updates of incretin‐related drugs for the treatment of type 2 diabetes
by: Hirotaka Araki, et al.
Published: (2023-02-01)

Glucose-Dependent Insulinotropic Peptide Level Is Associated with the Development of Type 2 Diabetes Mellitus
by: Sunghwan Suh, et al.
Published: (2016-03-01)

Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
by: Jared Rosenberg, et al.
Published: (2021-09-01)

Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis
by: Akira Mima, et al.
Published: (2023-03-01)

Tirzepatide for type 2 diabetes
by: Sarah L Anderson, et al.
Published: (2023-08-01)

Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
by: Chang Ho Ahn, et al.
Published: (2023-02-01)